Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Domain antibodies: proteins for therapy.

Lucy J Holt1, Chris Herring, Laurent S Jespers

  • 1Domantis Limited, Granta Park, Abington, Cambridge CB1 6GS, UK. lucy.holt@domantis.com

Trends in Biotechnology
|October 24, 2003
PubMed
Summary

Domain antibodies (dAbs) are small, stable antigen-binding fragments derived from heavy chain immunoglobulins. These highly expressed, soluble antibody fragments offer versatile formatting for enhanced drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel microchip-based imaged CIEF-MS system for comprehensive characterization and identification of biopharmaceutical charge variants.

Electrophoresis·2019
Same author

Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo.

Basic & clinical pharmacology & toxicology·2019
Same author

Antibody engineering and therapeutics conference. The annual meeting of the antibody society, Huntington Beach, CA, December 7-11, 2014.

mAbs·2014
Same author

Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat.

Cardiovascular diabetology·2013
Same author

Creation of the large and highly functional synthetic repertoire of human VH and Vκ domain antibodies.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

Methods for determining the PK parameters of AlbudAbs™ and of long serum half-life drugs made using the AlbudAb™ technology.

Methods in molecular biology (Clifton, N.J.)·2012

Area of Science:

  • Biotechnology
  • Immunology
  • Protein Engineering

Background:

  • Domain antibodies (dAbs) are naturally occurring fragments of heavy chain immunoglobulins found in camelids.
  • They represent the smallest known antigen-binding antibody fragments, with molecular weights between 11 kDa and 15 kDa.
  • dAbs are derived from the variable regions of heavy (VH) and light (VL) immunoglobulin chains.

Purpose of the Study:

  • To describe the characteristics and potential applications of domain antibodies (dAbs).
  • To highlight the advantages of dAbs in biopharmaceutical development.
  • To emphasize their suitability for in vitro selection and therapeutic formatting.

Main Methods:

  • Production of fully human domain antibodies (dAbs).
  • High-level expression in microbial cell culture systems.

Related Experiment Videos

  • Characterization of biophysical properties, including solubility and thermal stability.
  • Application of in vitro selection systems, such as phage display, for affinity maturation.

    • Main Results:

    • Domain antibodies (dAbs) exhibit favorable biophysical properties, including excellent solubility and temperature stability.
    • They demonstrate high expression levels in microbial cell cultures.
    • dAbs are effective as monomers and can be engineered into larger formats.

    Conclusions:

    • Domain antibodies (dAbs) are robust, small-sized antibody fragments with significant therapeutic potential.
    • Their inherent stability and ease of production make them highly suitable for drug development.
    • dAbs can be formatted to achieve prolonged serum half-lives and other desired pharmacological activities.